RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2015; 113(06): 1165-1169
DOI: 10.1160/TH15-02-0154
DOI: 10.1160/TH15-02-0154
Current Controversies
Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
Authors
Weitere Informationen
Publikationsverlauf
Received:
19. Februar 2015
Accepted after major revision:
04. März 2015
Publikationsdatum:
18. November 2017 (online)
-
References
- 1 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
- 2 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
- 3 You JJ, Singer DE, Howard PA. et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest 2012; 141: e531S-e575S.
- 4 Verma A, Cairns JA, Mitchell LB. et al. Committee CCSAFG. 2014 focused update of the canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30: 1114-1130.
- 5 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace 2012; 14: 1385-1413.
- 6 Gallego P, Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
- 7 De Caterina R, Husted S, Wallentin L. et al. Vitamin k antagonists in heart disease: Current status and perspectives (section iii). Position paper of the esc working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013; 110: 1087-1107.
- 8 Suzuki S, Yamashita T, Okumura K. et al. Incidence of ischaemic stroke in japanese patients with atrial fibrillation not receiving anticoagulation therapy. Circ J. 2014. Epub ahead of print
- 9 Okumura K, Inoue H, Atarashi H. et al. Investigators JRR. Validation of cha(2)ds(2)-vasc and has-bled scores in japanese patients with nonvalvular atrial fibrillation: An analysis of the j-rhythm registry. Circ J 2014; 78: 1593-1599.
- 10 Singer DE, Chang Y, Borowsky LH. et al. A new risk scheme to predict ischaemic stroke and other thromboembolism in atrial fibrillation: The atria study stroke risk score. J Am Heart Assoc 2013; 02: e000250.
- 11 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
- 12 Petersen P, Boysen G, Godtfredsen J. et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The copenhagen afasak study. Lancet 1989; 01: 175-179.
- 13 Connolly SJ, Laupacis A, Gent M. et al. Canadian atrial fibrillation anticoagulation (cafa) study. J Am Coll Cardiol 1991; 18: 349-355.
- 14 Go AS, Hylek EM, Borowsky LH. et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (atria) study. Ann Intern Med 1999; 131: 927-934.
- 15 Wang TJ, Massaro JM, Levy D. et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The framingham heart study. J Am Med Assoc 2003; 290: 1049-1056.
- 16 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
- 17 Olesen JB, Lip GY, Hansen ML. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. Br Med J 2011; 342: d124.
- 18 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The swedish atrial fibrillation cohort study. Eur Heart J 2012; 33: 1500-1510.
- 19 Mikkelsen AP, Lindhardsen J, Lip GY. et al. Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study. J Thromb Haemost 2012; 10: 1745-1751.
- 20 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
- 21 Eckman MH, Singer DE, Rosand J. et al. Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011; 04: 14-21.
- 22 Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-2307.
- 23 Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a cha2ds2-vasc score of 1. J Am Coll Cardiol 2015; 65: 225-232.
- 24 Olson KL, Wood MD, Delate T. et al. Positive predictive values of icd-9 codes to identify patients with stroke or tia. Am J Manag Care 2014; 20: e27-e34.
- 25 Andersen LV, Lip GY, Lindholt JS. et al. Upper limb arterial thromboembolism: A systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs. J Thromb Haemost 2013; 11: 836-844.
- 26 Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: Report from the stockholm cohort study of atrial fibrillation. Europace 2011; 13: 626-633.
- 27 Friberg J, Buch P, Scharling H. et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666-672.
- 28 Singer DE, Ezekowitz MD. Adding rigor to stroke risk prediction in atrial fibrillation. J Am Coll Cardiol 2015; 65: 233-235.
- 29 Chao TF, Liu CJ, Wang KL. et al. Should atrial fibrillation patients with 1 additional risk factor of the cha2ds2-vasc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 2015; 65: 635-642.
- 30 Huang D, Anguo L, Yue WS. et al. Refinement of ischaemic stroke risk in patients with atrial fibrillation and cha2 ds2 -vasc score of 1. Pacing Clin Electrophysiol 2014; 37: 1442-1447.
- 31 Lane DA, Lip GY. Patient’s values and p References for stroke prevention in atrial fibrillation: Balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: 381-383.
- 32 Lahaye S, Regpala S, Lacombe S. et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-473.
- 33 Ogilvie IM, Newton N, Welner SA. et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: 638-645 e634.
- 34 Le Heuzey JY, Ammentorp B, Darius H. et al. Differences among western european countries in anticoagulation management of atrial fibrillation. Data from the prefer in af registry. Thromb Haemost 2014; 111: 833-841.